(Date
of
Event which Requires Filing of this Statement)
If
the
filing person has previously filed a statement on Schedule 13G to report the
acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following
box
o.
Note:
Schedules filed in paper format shall include a signed original and five copies
of the schedule, including all exhibits. See
Rule
13d-7(b) for other parties to whom copies are to be sent.
*The
remainder of this cover page shall be filled out for a Reporting Person's
initial filing on this form with respect to the subject class of securities,
and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The
information required on the remainder of this cover page shall not be deemed
to
be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934
("Act") or otherwise subject to the liabilities of that section of the Act
but
shall be subject to all other provisions of the Act (however, see the
Notes).
(Continued
on Following Pages)
(Page
1
of 7 Pages)
CUSIP
No. 452530 10 1
13D
Page 2
of 6
1.
NAME
OF REPORTING PERSONS: Douglas McClain, Jr.
IRS
IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY):
____________
2.
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
□
(b)
□
3.
SEC
USE ONLY
4.
SOURCE
OF FUNDS
OO
5.
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO
ITEMS 2(d) OR 2(e)
□
6.
CITIZENSHIP
OR PLACE OF ORGANIZATION
United
States
NUMBER
OF
SHARES
BENEFICIALLY
OWNED
BY EACH
REPORTING
PERSON
WITH
7.
SOLE
VOTING POWER
0
8.
SHARED
VOTING POWER
93,600,000*
9.
SOLE
DISPOSITIVE POWER
0
10.
SHARED
DISPOSITIVE POWER
93,600,000*
11.
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
114,100,000*
12.
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
□
13.
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
41.9%
14.
TYPE
OF REPORTING PERSON
IN
*See
Item
5 hereof.
CUSIP
No. 452530 10 1
13D
Page 3
of 6
ITEM
1. SECURITY AND ISSUER
This
initial statement on Schedule 13D (this “Schedule
13D”)
relates to the common stock, par value $0.0001 per share (the “Common
Stock”),
of
Immunosyn Corporation, a Delaware corporation (the “Issuer”).
The
principal executive office of the Issuer is located at 4225 Executive Square,
Suite 260, La Jolla, California92037.
ITEM
2. IDENTITY AND BACKGROUND
This
Schedule 13D is filed by Douglas McClain, Jr. (“McClain”),
the
reporting person (the “Reporting
Person”).
Exhibit A also sets forth the name, business address, present principal
occupation and other information with respect to the Reporting
Person.
McClain
is the beneficial owner of 114,100,000 shares of Common Stock of the Issuer.
Such shares are held through the entities described in Item 3. Except as
described in Item 3, there is no agreement or arrangement by McClain with others
with respect to the voting or disposition of any securities of the Issuer
beneficially owned by McClain.
During
the five years prior to the date hereof, the Reporting Person has not (i) been
convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors) or (ii) been a party to a civil proceeding of a judicial or
administrative body of competent jurisdiction, as a result of such proceeding
such person was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such
laws.
ITEM
3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
The
Reporting Person is a 50% owner of Argyll Biotechnologies, LLC, a Delaware
limited liability company (“Argyll Biotech”). Argyll Biotech is jointly
controlled by its members, James T. Miceli and McClain and there is no agreement
or arrangement among the two members of Argyll Biotech with respect to the
voting or disposition of any securities of the Issuer owned by Argyll Biotech.
Pursuant to the terms of a license agreement between the Issuer and Argyll
Biotech, executed on September 28, 2006, Argyll Biotech was given 147,000,000
shares of Common Stock of the Issuer, in exchange for an exclusive worldwide
right to market, distribute, sell and promote SF-1019 for treatment of CIPD,
diabetic neuropathy and diabetic ulcers and certain other rights.
The
Reporting Person is a 50% owner of Argyll Equities, LLC, a Texas limited
liability company (“Argyll Equities”). Argyll Equities is jointly controlled by
its members, James T. Miceli and McClain and there is no agreement or
arrangement among the two members of Argyll Equities with respect to the voting
or disposition of any securities of the Issuer owned by Argyll Equities. Argyll
Equities purchased 15,000,000 shares of Common Stock from the Issuer on August4, 2006 in a privately negotiated transaction for $1,500.00. The source of
funds
for the purchase was the working capital of Argyll Equities.
The
Reporting Person is the 100% owner of Clairsvelle Holdings, Ltd., a British
Virgin Islands company (“Clairsvelle”). Mr. Lynn Booker has nominal control over
the voting and disposition of the Common Stock subject to the interests of
the
beneficial owner, McClainClairsvelle
purchased 20,500,000 shares of Common Stock from the Issuer on August 4, 2006
in
a privately negotiated transaction for $2,050.00. The source of funds for the
purchase was the working capital of Clairsvelle.
The
Reporting Person is the 45% owner of Padmore Holdings, Ltd., a British Virgin
Islands company (“Padmore”). Padmore is jointly owned by James T. Miceli,
McClain and Douglas McClain, Sr., whose
CUSIP
No. 452530 10 1
13D
Page 4
of 6
interests
are 45%, 45% and 10%, respectively. Mr. Lynn Booker has nominal control over
the
voting and disposition of the Common Stock subject to the interests of the
beneficial owners which interests shall be determined exclusively by Messrs
James T. Miceli and McClain. Padmore
purchased 28,000,000 shares of Common Stock from the Issuer on August 4,2006 in
a privately negotiated transaction for $2,800.00. The source of funds for
the
purchase was the working capital of Padmore.
ITEM
4. PURPOSE OF TRANSACTION
The
Common Stock owned by Argyll Biotech was acquired pursuant to the terms of
the
above-described license agreement as consideration for the grant of the license.
The Common Stock owned by Argyll Equities, a founder of the Issuer, was
purchased from the Issuer in a privately negotiated transaction in which Argyll
Equities invested $1,500.00 in the Issuer. The Common Stock owned by
Clairsvelle, a founder of the Issuer, was purchased from the Issuer in a
privately negotiated transaction in which Clairsvelle invested $2,050.00 in
the
Issuer. The Common Stock owned by Padmore, a founder of the Issuer, was
purchased from the Issuer in a privately negotiated transaction in which Padmore
invested $2,800.00 in the Issuer.
Although
the Reporting Person has not formulated any definitive plans not heretofore
disclosed or set forth herein, the Reporting Person may, from time to time
directly or indirectly through the entities described in Item 3 or otherwise,
acquire Common Stock of the Issuer or dispose of Common Stock of the Issuer
through open-market or privately negotiated transactions or otherwise if and
when deemed appropriate. The Reporting Person may formulate other purposes,
plans or proposals relating to any of such securities of the Issuer to the
extent deemed advisable in light of market conditions, investment policies
and
other factors.
Except
as
set forth in this Schedule 13D, the Reporting Person does not presently have
any
specific plans or proposals that relate to or would result in any of the actions
described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
ITEM
5. INTEREST IN SECURITIES OF THE ISSUER
The
Reporting Person’s beneficial ownership is as follows:
(a)
Amount beneficially owned: 114,100,000 shares of Common Stock Percent
of class: 41.9% based on 272,000,000 shares of Common Stock issued and
outstanding
(b)
Number of shares as to which the Reporting Person has:
(i)
Sole
power to vote or to direct the vote - 0
(ii)
Shared power to vote or to direct the vote -93,600,000*
(iii)
Sole power to dispose or to direct the disposition of - 0
(iv)
Shared power to dispose or to direct the disposition of -
93,600,000*
(c)
The
information with respect to the acquisition of beneficial interest in the Common
Stock of the Issuer by the Reporting Person, as set forth in Item 3, is hereby
incorporated by reference.
(d) Not
applicable.
(e) Not
applicable.
_________________
*
Does
not include 20,500,000 shares of Common Stock purchased in a privately
negotiated transaction
between the Issuer and Clairsvelle. Mr. Lynn Booker has the power to vote
and
CUSIP
No. 452530 10 1
13D
Page 5
of 6
dispose
of, or direct the vote or disposition of, 20,500,000 shares of Common Stock
of
the Issuer owned
by
Clairsvelle, subject to the interests of the Reporting Person.
ITEM
6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO
SECURITIES OF THE ISSUER
None.
ITEM
7. MATERIAL TO BE FILED AS EXHIBITS
Exhibit
A
- Information concerning the Reporting Person
CUSIP
No. 452530 10 1
13D
Page 6
of 6
SIGNATURE
After
reasonable inquiry and to the best of his or its knowledge and belief, each
of
the undersigned certifies that the information set forth in this Schedule 13D
is
true, complete and correct.
Principal
Occupation: Business executive with Argyll Equities, LLC, 4225 Executive Square,
Suite 260, La Jolla, California92037 which engages in the private investment
business
Citizenship:
United States
Dates Referenced Herein and Documents Incorporated by Reference